# HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

> **NCT07425054** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jennifer Dorth** · enrollment: 33 (estimated)

## Conditions studied

- Anal Cancer
- HPV-Related Carcinoma
- Squamous Cell Carcinoma of the Anus

## Interventions

- **RADIATION:** HPV ctDNA Response based radiation
- **DRUG:** Chemotherapy
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT07425054
- **Lead sponsor:** Jennifer Dorth
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425054, "HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07425054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*